The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Size Growth Is Projected For The Inflammatory Bowel Disease Treatment Market During The Forecast Period 2026–2030?
The inflammatory bowel disease treatment market size has experienced significant expansion over recent years. This market is projected to expand from $27.19 billion in 2025 to $29.8 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 9.6%. The factors contributing to its historical growth include the increasing prevalence of ulcerative colitis and crohn’s disease, enhanced awareness regarding IBD treatment options, the broadening of hospital and retail pharmacy networks, the accessibility of generic aminosalicylates, and the early integration of biologics in developed regions.
The market for inflammatory bowel disease treatments is set to experience significant expansion over the next few years, with projections indicating it will reach $43.36 billion by 2030, achieving a compound annual growth rate (CAGR) of 9.8%. This anticipated growth throughout the forecast period can be attributed to increased funding in precision medicine, the development of new anti-inflammatory therapies, the integration of digital health platforms for patient monitoring, a rise in the adoption of biologics and biosimilars, and expanded access to IBD treatment in developing markets. Noteworthy trends during this period include the advancement of personalized IBD therapies, a growing reliance on biologics for treatment, the emergence of minimally invasive drug delivery systems, an elevated focus on patient adherence programs, and the proliferation of specialty pharmacies catering to IBD.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=6704&type=smp
What Drivers Are Expected To Influence The Inflammatory Bowel Disease Treatment Market During The Forecast Period?
The increasing occurrence of Crohn’s disease and ulcerative colitis is a major catalyst for the inflammatory bowel disease treatment market. These conditions are forms of inflammatory bowel diseases (IBD), characterized by inflammation and ulcers (sores) within the digestive system. The growing number of Crohn’s disease and ulcerative colitis cases is anticipated to heighten the need for inflammatory bowel disease treatments, given their extensive use in alleviating bowel inflammation and mitigating or avoiding health complications. For example, data from November 2024, provided by the Crohn’s & Colitis Foundation, a US-based Non-profit organization, indicates that around 100,429 children and adolescents in the United States, aged under 20, suffer from IBD, which includes both Crohn’s disease and ulcerative colitis. Within this younger demographic, Crohn’s disease is more prevalent, affecting 71 per 100,000 individuals, while ulcerative colitis stands at 44 per 100,000. Consequently, the expanding incidence of Crohn’s disease and ulcerative colitis is projected to fuel the growth of the inflammatory bowel disease treatment market.
What Market Segments Are Evaluated Within The Inflammatory Bowel Disease Treatment Market?
The inflammatory bowel disease treatment market covered in this report is segmented –
1) By Drug Class: Aminosalicylates, Corticosteroids, TNF inhibitors, IL inhibitors, Anti-integrin, JAK inhibitors, Other Drug Classes
2) By Type: Crohn’s Disease, Ulcerative Colitis
3) By Route Of Administration: Oral, Injectable
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Subsegments:
1) By Aminosalicylates: Mesalamine, Sulfasalazine, Balsalazide
2) By Corticosteroids: Prednisone, Budesonide, Hydrocortisone
3) By TNF Inhibitors: Infliximab, Adalimumab, Certolizumab pegol
4) By IL Inhibitors: Ustekinumab, Guselkumab
5) By Anti-Integrin: Vedolizumab, Natalizumab
6) By JAK Inhibitors: Tofacitinib, Filgotinib
7) By Other Drug Classes: Antibiotics, Immunosuppressants, Other Novel Therapies
What Industry Trends Are Redefining The Inflammatory Bowel Disease Treatment Market?
Leading companies operating in the inflammatory bowel disease treatment market are developing innovative products, such as therapies for moderate to severe active ulcerative colitis, to reach broader customer bases, increase sales, and boost revenue. Treatments for moderate to severe active ulcerative colitis typically involve medications and sometimes surgical interventions. For instance, in October 2023, Eli Lilly and Company, a US-based pharmaceutical company, announced the U. S. Food and Drug Administration (FDA) approval for Omvoh (mirikizumab-mrkz). Available in both infusion (300 mg/15 mL) and injection (100 mg/mL) forms, it is the inaugural and sole interleukin-23p19 (IL-23p19) antagonist designed for adults with moderately to severely active ulcerative colitis (UC). Omvoh is specifically tailored to focus on the p19 subunit of IL-23, effectively blocking the IL-23 pathway, which is responsible for the inflammation that significantly contributes to the development of UC. The Omvoh treatment regimen begins with three 300-mg IV infusions, administered once a week every four weeks, and then shifts to a maintenance phase involving two 100-mg subcutaneous self-injections every four weeks.
Who Are The Top Market Participants Influencing The Inflammatory Bowel Disease Treatment Market?
Major companies operating in the inflammatory bowel disease treatment market are AbbVie Inc., Biogen Inc., Johnson & Johnson, Amgen Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, Gilead Sciences Inc., GlaxoSmithKline plc, Merck & Co. Inc., Novartis International AG, Pfizer Inc., F. Hoffmann-La Roche Ltd, Takeda Pharmaceutical Company Limited, Salix Pharmaceuticals Inc., Vifor Pharma AG, Zydus Pharmaceuticals (USA) Inc., Advanced Gastroenterology and Surgery Associates P.A., Atlanta Gastroenterology Associates LLC, Digestive Disease Associates of Rockland P.C., Gastrointestinal Specialists Inc., Illinois Gastroenterology Group LLC, Massachusetts General Hospital, Mayo Clinic, Mount Sinai Health System Inc., The Oregon Clinic – Gastroenterology West P.C.
Read the full inflammatory bowel disease treatment market report here:
Which Region Is Forecast To Lead The Inflammatory Bowel Disease Treatment Market In Terms Of Market Size?
North America was the largest region in the inflammatory bowel disease treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the inflammatory bowel disease treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Inflammatory Bowel Disease Treatment Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=6704&type=smp
Browse Through More Reports Similar to the Global Inflammatory Bowel Disease Treatment Market 2026, By The Business Research Company
Inflammatory Bowel Disease Treatment Market Report 2026
Crohns Disease Treatment Market Report 2026
https://www.thebusinessresearchcompany.com/report/crohns-disease-treatment-global-market-report
Rare Inflammatory Disease Treatment Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model